PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer.
Fahad Shabbir AhmedPatricia GauleJohn McGuireKatir PatelKim R M BlenmanLajos PusztaiDavid L RimmPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Expression of PD-L1 in tumor cells, immune cells in stroma, and colocalized with CD68+ cells is associated with higher rates of pCR to durvalumab and chemotherapy in TNBC.